A Shanghai-based integrated biopharmaceutical company, Jiangsu Hengrui Medicine and Arcutis, a Menlo Park, CA-based Biotechnology Company declared licensing agreement to commercialize applications of Hengrui’s drug, SHR0302 to diagnose disorders of dermatology which is currently under assessment in phase 2 clinical trials in China for rheumatoid arthritis.
Lianshan Zhang, Ph.D., President of Global R&D of Hengrui said “There is a high unmet need for a topical therapy with a new mechanism of action to effectively address immune-mediated dermatology disorders. We are very excited to be a partner of Arcutis.”
An intracellular pathway, JAK-STAT plays a vital role in immune and hematopoietic function upon which several varied proinflammatory signals converge. SHR0302 set to extend tissue half-life and a clinical development is being pursued in China as a therapy to cure an array of autoimmune disorders. Studies are disclosing the manifestation of optimistic usage of JAK inhibitors in dermatology.